Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

Besides knowing what different patterns of infection exist across advanced therapies, what is “really important” is how ...

Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some ...

Scientists identify the complex interplay between immune dysfunction, genetics, environment and disease progression driving ...

Given the dramatic changes in GLP-1 and biologic treatments and their rapid adoption, real-world data illuminating patient feedback and prescriber rationale is essential.” — Chris Baker, Amplity CEO ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

The injectable medication, which contains the active ingredient adalimumab, is used to treat rheumatoid arthritis and other inflammatory conditions. Biktarvy is an HIV treatment that includes the ...

Trading in the Company’s SDRs on Nasdaq Stockholm commences on Monday, May 19, 2025, under the trading symbol (ticker) “ALVO SDB”. Settlement is expected to take place on May 21, 2025.

Hidradenitis suppurativa (HS) is a refractory and recurrent chronic inflammatory skin disease characterized by nodules, abscesses, sinus tracts, and scarring. The etiology of HS remains unclear, ...

Now that the likes of Remicade (infliximab), Enbrel (etanercept) and, most importantly, Humira (adalimumab) have to compete with biosimilar versions, the NHS is grappling with how to make the most ...